GW Pharmaceuticals to Present at the Piper Jaffray 25th Annual Health Care Conference

London, UK, 2 December 2013: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW’s Chief Executive Officer, is scheduled to present at the Piper Jaffray 25th Annual Health Care Conference on Wednesday, 4 December, 2013 at 8:30 a.m. ET. The conference will be held at the New York Palace Hotel in New York City.

A live audio webcast of the presentation will be available through GW’s corporate website in the investor relations section from the investor’s calendar of events page at www.gwpharm.com. A replay will be available soon after the live presentation.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 23 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has established a world leading position in the development of plant-derived cannabinoid therapeutics and has a deep pipeline of additional clinical-stage cannabinoid product candidates targeting epilepsy (including an orphan pediatric epilepsy program), Type 2 diabetes, ulcerative colitis, glioma and schizophrenia.www.gwpharm.com.

Enquiries:

GW Pharmaceuticals plc
Justin Gover, Chief Executive Officer
Stephen Schultz, VP Investor Relations (US)
(Today) + 44 20 7831 3113
(Thereafter) + 44 1980 557000
+ 1 401 500 6570
FTI Consulting (Media Enquiries)
Ben Atwell / Simon Conway / John Dineen (UK)
Robert Stanislaro (US)
+ 44 20 7831 3113
+1 212 850 5657
Trout Group, LLC (US investor relations)
Todd James / Chad Rubin
+1 646 378 2900

 

Tags: , , , , , ,